

Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $149.15
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| May 4, 26 | Barclays |
| maintain |
| Overweight |
| Overweight |
| Mar 2, 26 | DA Davidson | maintain | Buy | Buy |
| Nov 3, 25 | Barclays | maintain | Overweight | Overweight |
| Aug 11, 25 | DA Davidson | maintain | Buy | Buy |
| Jan 14, 25 | Oppenheimer | maintain | Outperform | Outperform |
| Aug 19, 24 | Oppenheimer | maintain | Outperform | Outperform |
| Aug 7, 24 | Stephens & Co. | upgrade | Equal Weight | Overweight |
| May 17, 24 | DA Davidson | maintain | Buy | Buy |
| May 6, 24 | DA Davidson | maintain | Buy | Buy |
1254 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-22
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 81.97 | Oscillator | Sell |
| Stochastic %K (14, 3, 3) | 92.65 | Oscillator | Sell |
| Williams %R (14) | -2.07 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.67 (Hist 0.18) | Oscillator | Strong Buy |
| Average Directional Index (14) | 44.29 (+DI 37.3 / -DI 6.4) | Trend | Strong Buy |
| EMA 20 | 147.17 | MA | Buy |
| SMA 20 | 147.01 | MA | Buy |
| EMA 50 | 145.70 | MA | Buy |
| SMA 50 | 146.08 | MA | Buy |
| SMA 200 | 129.84 | MA | Strong Buy |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 23, 2026 | 2026-10-23 16:46:37 | View |
| 4 | Oct 23, 2026 | 2026-10-23 16:46:32 | View |
| 4 | Oct 23, 2026 | 2026-10-23 16:46:27 | View |
| 4 | Oct 23, 2026 | 2026-10-23 16:46:22 | View |
| 4 | Oct 23, 2026 | 2026-10-23 16:46:16 | View |
| 4 | Oct 23, 2026 | 2026-10-23 16:46:10 | View |
| 4 | Oct 23, 2026 | 2026-10-23 16:46:04 | View |
| 4 | Oct 23, 2026 | 2026-10-23 16:45:58 | View |
| 4 | Oct 23, 2026 | 2026-10-23 16:45:53 | View |
| 4 | Oct 23, 2026 | 2026-10-23 16:45:46 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 23, 26 | Cole Kerry S | officer: Group President | A-Award | 24,702 | — |
| Oct 23, 26 | Cole Kerry S | officer: Group President | D-Return | 52,189 @ $150.00 | $7.83M |
| Oct 23, 26 | Demetriou Steven J. | director | D-Return | 12,611 @ $150.00 | $1.89M |
| Oct 23, 26 | Peck Gail M | officer: Chief Financial Officer | A-Award | 43,264 | — |
| Oct 23, 26 | Peck Gail M | officer: Chief Financial Officer | D-Return | 128,956 @ $150.00 | $19.34M |
| Oct 23, 26 | Carrillo Antonio | director, officer: President & CEO | A-Award | 168,305 | — |
| Oct 23, 26 | Carrillo Antonio | director, officer: President & CEO | D-Return | 667,240 @ $150.00 | $100.1M |
| Oct 23, 26 | Carrillo Antonio | director, officer: President & CEO | D-Return | 4,887 | — |
Stock news · updated daily
NEW YORK, Oct. 23, 2026 /PRNewswire/ -- Howard Hughes Holdings Inc. (NYSE: HHH) will replace Arcosa Inc. (NYSE: ACA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 28. S&P 500 constituent CRH plc (NYSE: CRH) has acquired Arcosa in a deal that closed today, October 23.
State of Alaska Department of Revenue lowered its position in Arcosa, Inc. (NYSE: ACA) by 46.1% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,303 shares of the company's stock after selling 8,798 shares during
Arcosa (NYSE: ACA - Get Free Report) and Vulcan Materials (NYSE: VMC - Get Free Report) are both materials companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends. Profitability This table compares Arcosa and Vulcan Materials' net
Oscar Health's ACA marketplace expansion fuels growth prospects, but subsidy uncertainty, rising medical costs and pricing risks could challenge lasting profits.
DALLAS--(BUSINESS WIRE)--Arcosa, Inc. (NYSE: ACA) (“Arcosa” or the “Company”), a provider of infrastructure-related products and solutions, today announced it will hold quarterly bondholder calls for the benefit of the holders of the Notes, the Trustee, beneficial owners of the Notes, prospective purchasers of the Notes, securities analysts and market making financial institutions to ask questions following the release of its quarterly financial information, beginning with the Quarterly Report.
Corient Private Wealth LP grew its holdings in Arcosa, Inc. (NYSE: ACA) by 284.9% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,111 shares of the company's stock after acquiring an additional 8,224 shares during the quarter. Corient Private Wealth
Shares of Arcosa, Inc. (NYSE: ACA - Get Free Report) have been assigned a consensus recommendation of "Hold" from the seven research firms that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price
DALLAS--(BUSINESS WIRE)--Arcosa, Inc. (NYSE: ACA) (“Arcosa” or the “Company”), a provider of infrastructure-related products and solutions, today announced that the Company's stockholders approved the acquisition by CRH (NYSE: CRH) at its special meeting on September 4, 2026. Arcosa will disclose the final, certified voting results on a Form 8-K with the U.S. Securities and Exchange Commission. As previously announced, Arcosa and CRH have entered into a merger agreement for CRH to acquire 100%.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | 1.19 | 1.13 | Miss -5.0% | $658.7M |
| Apr 30, 2026 | 0.13 | 0.51 | Beat 292.3% | $571.7M |
| Feb 26, 2026 | 0.95 | 1.15 | Beat 21.1% | $716.7M |
| Oct 30, 2025 | 1.33 | 1.56 | Beat 17.3% | $797.8M |
| Aug 7, 2025 | 1.05 | 1.27 | Beat 21.0% | $736.9M |
| May 6, 2025 | 0.29 | 0.49 | Beat 69.0% | $632.0M |
TTM vs. 5-year historical average (annual ratios)
| Metric | ACA | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 14.9x | 29.6x · sector 16.6x | In line |
| Forward P/E (FY26E) | 34.8x | EPS est. 4.28 | Elevated |
| Price / Book | 2.5x | 1.6x | Elevated |
| Price / Sales | 2.7x | 1.6x | Elevated |
| EV / EBITDA | 15.1x | 11.5x | Elevated |
| Return on equity | 18.2% | — | Healthy |
| Gross margin | 23.0% | 19.5% | Above hist. |
| Debt / Equity | 0.48 | 0.44 | Conservative |
| Piotroski / Altman Z | 6/9 | Z 3.18 | Safe zone |
Discounted cash flow model
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure